Thyroid Study Type 2 Diabetes Mellitus (T2DM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Maastricht University Medical Center
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01379170
First received: June 21, 2011
Last updated: May 13, 2013
Last verified: May 2013
  Purpose

Background of the study:

Thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to promote weight loss, which could be beneficial for treating obesity, and type 2 diabetes. Thyroid hormone treatment stimulates energy expenditure resulting in increased body heat production, in which brown adipose tissue play an important role. It is hypothesized that thyroid hormones would induce increased energy expenditure via a process called mitochondrial uncoupling, thereby creating an inefficient energy status. Indeed, an in vivo study showed a 70% increased flux through the tricarboxylic acid cycle (TCA) and an unchanged ATP synthesis rate upon T3 treatment in lean, healthy young men. The disproportionate increase in TCA flux compared with ATP synthesis suggests increased mitochondrial uncoupling. It is however unknown whether increased mitochondrial uncoupling would increase fat oxidation and exerts favorable effects on insulin sensitivity. There is compelling evidence that type 2 diabetic patients have high levels of fat accumulation in non-adipose tissues, such as skeletal muscle, heart and liver. Ectopic fat accumulation is related to insulin resistance, however, why this fat accumulates in peripheral organs is not known. Recently, studies reported compromised mitochondrial oxidative capacity in type 2 diabetic patients and first-degree relatives of diabetic patients, suggested to play an important role. Therefore, subjects suffering from overweight and/or type 2 diabetes with overt hypothyroidism form an interesting group for examining the metabolic effects of thyroid hormone treatment, as less is known about the effects of thyroid hormone treatment in these groups.

Objective of the study:

The purpose of this study is to evaluate whether thyroid hormone replacement therapy in type 2 diabetic patients suffering from overt hypothyroidism, will improve muscular mitochondrial function, lower ectopic fat accumulation in muscle and liver, increase brown adipose tissue activity and enhance insulin sensitivity.

Study design:

Type 2 diabetic patients diagnosed with hypothyroidism will undergo 3 months of thyroid hormone replacement therapy (THRT) (Euthyrox®, Merck, Germany). Patients will be metabolically characterized (such as insulin sensitivity and fat accumulation in peripheral tissues) before and after this thyroid hormone replacement therapy.

Study population:

17 type 2 diabetic patients diagnosed with overt hypothyroidism (9 from the Netherlands, 8 from Germany which will only do the PET-CT)

Primary study parameters/outcome of the study:

Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function.

Secondary study parameters/outcome of the study (if applicable):

Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity.


Condition Intervention Phase
Diabetes
Hypothyroidism
Drug: Euthyrox (levothyroxine)
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    see title


Secondary Outcome Measures:
  • Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    see title


Estimated Enrollment: 17
Study Start Date: June 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Type 2 diabetes, de novo hypothyrodism treatment
Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
Drug: Euthyrox (levothyroxine)
A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
Other Name: Euthyrox/levothyroxine

  Eligibility

Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or postmenopausal females
  • Age 40-65 years
  • Body mass index (BMI) < 40 and > 27 kg/m2
  • Stable dietary habits (no weight loss/gain >3 kg in the last 6 months)
  • Stable physical activity levels for at least six months
  • Newly diagnosed hypothyroid, non-insulin dependent type 2 diabetic patients having TSH values higher then > 4.0 mU/l and lowered concentrations of free T4 < 8.0 pmol/l.
  • Type 2 diabetic patients using sulphonylurea and or metformin therapy for at least six months with a constant dose for at least two months.
  • Hypothyroid diabetic patients due to Hashimoto disease (TPO > 100 IE/ml; Tg > 344 IE/ml), should have no auto-antibodies against glutamic acid decarboxylase (GAD), IA-2 and insulin to exclude type 2 polyglandular autoimmune syndrome (PGAII) (to exclude type 1 diabetes).
  • Type 2 diabetic patients should have a HbA1c level < 8.0%
  • Type 2 diabetic patients will be included when having no diabetes-related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy.

Exclusion Criteria:

  • Unstable body weight
  • Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
  • Medical history including active cardiovascular disease, i.e. history of coronary artery disease (i.e. history of angina pectoris, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting) or cardiac arrhythmias.
  • Liver disease or liver dysfunction (ALT>2.5 x increased)
  • Impaired renal function (creatinine > 120 umol/L)
  • Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg
  • Hb <7.4 mmol/l (12 g/dl) in women, and <8.1 mmol/l (13 g/dl) in men
  • Abuse of drugs and/or alcohol
  • Contraindications for MRI scanning (please see appendix III: MRI contraindication questionnaire)
  • Patients with history of thyroid cancer
  • Patients using α and/or β blockers
  • Severe diabetes which requires application of insulin or patients with diabetes-related complications
  • History of psychiatric disease
  • Diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy.
  • Use of medications known to interfere with glucose homeostasis (i.e. corticosteroids, thiazolidinediones)
  • Hypothyroid diabetic patients due to Hashimoto disease with positive test values for auto-antibodies against GAD, IA-2 and insulin to exclude type 1 diabetes.
  • Use of anticoagulants, other than platelet aggregation inhibitors.
  • Patients that have donated blood in the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01379170

Contacts
Contact: Evie Broeders, MD +31 43 3884254 e.broeders@maastrichtuniversity.nl
Contact: Patrick Schrauwen, PhD +31 43 381502 p.schrauwen@maastrichtuniversity.nl

Locations
Netherlands
Maastricht University Medical Centre Recruiting
Maastricht, Limburg, Netherlands, 6200MD
Contact: Evie Broeders, MD    +31 43 3884254    e.broeders@maastrichtuniversity.nl   
Sponsors and Collaborators
Maastricht University Medical Center
  More Information

No publications provided

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01379170     History of Changes
Other Study ID Numbers: MEC10-3-085
Study First Received: June 21, 2011
Last Updated: May 13, 2013
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
brown adipose tissue
mitochondrial dysfunction
insulin resistance

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hypothyroidism
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Thyroid Diseases

ClinicalTrials.gov processed this record on August 26, 2014